The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Ítems similars

• The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  per: Syed, Maha N., et al.
  Publicat: (2020)
• Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic
  per: Syed, Maha N., et al.
  Publicat: (2021)
• Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”
  per: Wan, Marilyn T., et al.
  Publicat: (2020)
• Targeting of interleukin-17 in the treatment of psoriasis
  per: Lønnberg, Ann Sophie, et al.
  Publicat: (2014)
• Interleukin-17A and Keratinocytes in Psoriasis
  per: Furue, Masutaka, et al.
  Publicat: (2020)